A small molecule-kinase interaction map for clinical kinase inhibitors - PubMed (original) (raw)
doi: 10.1038/nbt1068. Epub 2005 Feb 13.
William H Biggs 3rd, Daniel K Treiber, Corey E Atteridge, Mihai D Azimioara, Michael G Benedetti, Todd A Carter, Pietro Ciceri, Philip T Edeen, Mark Floyd, Julia M Ford, Margaret Galvin, Jay L Gerlach, Robert M Grotzfeld, Sanna Herrgard, Darren E Insko, Michael A Insko, Andiliy G Lai, Jean-Michel Lélias, Shamal A Mehta, Zdravko V Milanov, Anne Marie Velasco, Lisa M Wodicka, Hitesh K Patel, Patrick P Zarrinkar, David J Lockhart
Affiliations
- PMID: 15711537
- DOI: 10.1038/nbt1068
Free article
A small molecule-kinase interaction map for clinical kinase inhibitors
Miles A Fabian et al. Nat Biotechnol. 2005 Mar.
Free article
Abstract
Kinase inhibitors show great promise as a new class of therapeutics. Here we describe an efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases. We have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clinical development, against a panel of 119 protein kinases. We find that specificity varies widely and is not strongly correlated with chemical structure or the identity of the intended target. Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK. We also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib. Our results represent a systematic small molecule-protein interaction map for clinical compounds across a large number of related proteins.
Comment in
- Interaction maps for kinase inhibitors.
Griffin JD. Griffin JD. Nat Biotechnol. 2005 Mar;23(3):308-9. doi: 10.1038/nbt0305-308. Nat Biotechnol. 2005. PMID: 15765084 No abstract available. - BIRB-796 is not an effective ABL(T315I) inhibitor.
O'Hare T, Druker BJ. O'Hare T, et al. Nat Biotechnol. 2005 Oct;23(10):1209-10; author reply 1210-1. doi: 10.1038/nbt1005-1209. Nat Biotechnol. 2005. PMID: 16211050 No abstract available. - Molecule-kinase interaction map.
Buolamwini JK, Kamath S. Buolamwini JK, et al. Nat Biotechnol. 2005 Nov;23(11):1346; author reply 1346-8. doi: 10.1038/nbt1105-1346a. Nat Biotechnol. 2005. PMID: 16273056 No abstract available.
Similar articles
- Interaction maps for kinase inhibitors.
Griffin JD. Griffin JD. Nat Biotechnol. 2005 Mar;23(3):308-9. doi: 10.1038/nbt0305-308. Nat Biotechnol. 2005. PMID: 15765084 No abstract available. - BIRB-796 is not an effective ABL(T315I) inhibitor.
O'Hare T, Druker BJ. O'Hare T, et al. Nat Biotechnol. 2005 Oct;23(10):1209-10; author reply 1210-1. doi: 10.1038/nbt1005-1209. Nat Biotechnol. 2005. PMID: 16211050 No abstract available. - Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D, Stehle T, Narula S, Schelling P, van Schravendijk MR, Adams S, Andrade L, Keats J, Ram M, Jin L, Grossman T, MacNeil I, Metcalf C 3rd, Shakespeare W, Wang Y, Keenan T, Sundaramoorthi R, Bohacek R, Weigele M, Sawyer T. Dalgarno D, et al. Chem Biol Drug Des. 2006 Jan;67(1):46-57. doi: 10.1111/j.1747-0285.2005.00316.x. Chem Biol Drug Des. 2006. PMID: 16492148 - A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA, Fairlie DP. Bogoyevitch MA, et al. Drug Discov Today. 2007 Aug;12(15-16):622-33. doi: 10.1016/j.drudis.2007.06.008. Epub 2007 Aug 2. Drug Discov Today. 2007. PMID: 17706543 Review. - Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C, Sattler M. Walz C, et al. Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. doi: 10.1016/j.critrevonc.2005.06.007. Epub 2005 Oct 5. Crit Rev Oncol Hematol. 2006. PMID: 16213151 Review.
Cited by
- Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads.
Bálint D, Póti ÁL, Alexa A, Sok P, Albert K, Torda L, Földesi-Nagy D, Csókás D, Turczel G, Imre T, Szarka E, Fekete F, Bento I, Bojtár M, Palkó R, Szabó P, Monostory K, Pápai I, Soós T, Reményi A. Bálint D, et al. Nat Commun. 2024 Oct 4;15(1):8606. doi: 10.1038/s41467-024-52573-2. Nat Commun. 2024. PMID: 39366946 Free PMC article. - Proteomic assessment of SKBR3/HER2+ breast cancer cellular response to Lapatinib and investigational Ipatasertib kinase inhibitors.
Karcini A, Mercier NR, Lazar IM. Karcini A, et al. Front Pharmacol. 2024 Aug 29;15:1413818. doi: 10.3389/fphar.2024.1413818. eCollection 2024. Front Pharmacol. 2024. PMID: 39268460 Free PMC article. - Deprotective Lossen rearrangement: a direct and general transformation of Nms-amides to unsymmetrical ureas.
Spieß P, Brześkiewicz J, Maulide N. Spieß P, et al. Chem Sci. 2024 Sep 10;15(38):15799-803. doi: 10.1039/d4sc04974h. Online ahead of print. Chem Sci. 2024. PMID: 39268216 Free PMC article. - Leveraging multiple data types for improved compound-kinase bioactivity prediction.
Theisen R, Wang T, Ravikumar B, Rahman R, Cichońska A. Theisen R, et al. Nat Commun. 2024 Aug 31;15(1):7596. doi: 10.1038/s41467-024-52055-5. Nat Commun. 2024. PMID: 39217147 Free PMC article. - A PIKfyve modulator combined with an integrated stress response inhibitor to treat lysosomal storage diseases.
Hou WC, Massey LA, Rhoades D, Wu Y, Ren W, Frank C, Overkleeft HS, Kelly JW. Hou WC, et al. Proc Natl Acad Sci U S A. 2024 Aug 20;121(34):e2320257121. doi: 10.1073/pnas.2320257121. Epub 2024 Aug 16. Proc Natl Acad Sci U S A. 2024. PMID: 39150784
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Molecular Biology Databases
Research Materials
Miscellaneous